Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03838835 · ClinicalTrials.gov registry record · NA
Equine Facilitated CBT Group Therapy for Youth Anxiety
A NA study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- NA
- Development phase
- 59
- Enrollment target
NCT03838835: Clinical Trial NA study, sponsored by NYU Langone Health.
NCT03838835 is a NA study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 59 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03838835, a NA study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- NA
- Development phase
- 59 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate a 10-week equine facilitated cognitive behavioral therapy (CBT) group program for youth between ages of 6 to 17 with symptoms of anxiety. The program will be delivered at GallopNYC, a stable that provides equine-facilitated group therapy to youth with a range of mental health problems.
Primary Outcome
41 item questionnaire scored on a 3-point Likert Scale ranging from "not true" to "very true." Items are summed, with higher scores indicating more anxiety symptoms (a cutoff of 25 indicates an anxiety disorder).
Interventions
- BEHAVIORAL Augmented equine-facilitated CBT group program
- BEHAVIORAL TAU is equine-facilitated group therapy
- OTHER WLC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2018-11-15 |
| Est. Completion | 2020-05-26 |
| Phase | NA |
Why NCT03838835 stopped before completion
NCT03838835 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 3 interventions - of which Augmented equine-facilitated CBT group program is the first listed.
NCT03838835 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03838835 about?
NCT03838835 is a clinical study titled "Equine Facilitated CBT Group Therapy for Youth Anxiety". The purpose of this study is to evaluate a 10-week equine facilitated cognitive behavioral therapy (CBT) group program for youth between ages of 6 to 17 with symptoms of anxiety. The program will be delivered at GallopNYC, a stable that provides equine-facilitated group therapy to youth with a range...
What is the current status of trial NCT03838835?
This trial is currently terminated. It is a NA study. The enrollment target is 59 participants. The study started on 2018-11-15. Estimated completion is 2020-05-26.
What interventions are being tested in trial NCT03838835?
The interventions under investigation include: Augmented equine-facilitated CBT group program (BEHAVIORAL), TAU is equine-facilitated group therapy (BEHAVIORAL), WLC (OTHER).
Who is sponsoring clinical trial NCT03838835?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03838835's enrollment target sits among peer trials
59 1256th of 2000 higher than 745 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI